Repligen company profile
Company profile
Repligen has 2,000 employees and is headquartered in Waltham, United States.
Biologic drug makers, contract manufacturers, diagnostic firms and bench-level researchers make up the customer base of Repligen Corporation, which develops bioprocessing technologies and systems in North America, Europe and the Asia Pacific region. Its offering spans filtration units such as cell retention systems and tangential flow cassettes, chromatography columns used to purify biological drugs, Protein A ligands, cell culture growth factors, ELISA kits, and process analytics instruments that monitor critical production parameters in real time. Products are sold under brands including OPUS, XCell, KrosFlo and SoloVPE. A collaboration agreement with Navigo Proteins GmbH covers the development of several affinity ligands.
In the fiscal year ended December 2025, Repligen reported revenue of 738.3 million US dollars, up 16.4% from the previous year, and net income of 48.9 million US dollars. The company had 2,000 employees. It was incorporated in 1981 and has its headquarters in Waltham, Massachusetts.
Company facts
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Headquarters
- Building 1, 02453, Waltham
- Employees
- 2,000
- Chief executive
- Olivier Loeillot
- Founded
- 1981
- Fiscal year
- January - December
- Listing
- RGEN · NASDAQ
- Currency
- USD
- ISIN
- US7599161095
- Website
- repligen.com
Repligen and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| RepligenRGEN | United States | $10.73B | 2,000 | 8.1% | — |
| AvantorAVTR | United States | $10.46B | 13,500 | 8.0% | 30.9 |
| Align TechnologyALGN | United States | $11.86B | 20,180 | 19.6% | 24.5 |
| Cooper CompaniesCOO | United States | $11.91B | 15,000 | 12.9% | 21.5 |
| AptarGroupATR | United States | $9.12B | 14,000 | 12.4% | 34.4 |
| Baxter InternationalBAX | United States | $13.39B | 37,500 | 7.6% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
